Dyslipidemia News

Increases in Hypertension, Diabetes, and Dyslipidemia During 10 Year Period - The Cardiology Advisor



The Cardiology Advisor
 
Increases in Hypertension, Diabetes, and Dyslipidemia During 10 Year Period 
The Cardiology Advisor
HealthDay News ? From 2004 to 2014 there were increases in the prevalence of hypertension, diabetes, dyslipidemia, smoking, and drug abuse in acute ischemic stroke (AIS), according to a study published in Neurology. Fadar Oliver Otite, MD, from the ...

 


LG Chem launches combination drug for diabetes, dyslipidemia in Korea - The Korea Herald



The Korea Herald
 
LG Chem launches combination drug for diabetes, dyslipidemia in Korea 
The Korea Herald
The combination tablet simultaneously treats diabetes and dyslipidemia, a condition in which an abnormal amount of lipids exist in the bloodstream. Developed by LG Chem's biopharmaceuticals unit, Zemiro is a new combination tablet that merges LG's ...
LG Chem launches combination drug for diabetes, dyslipidemia Korea Times

all 3 news articles » 


LG Chem launches Korea's 1st combination drug for diabetes, dyslipidemia - Korea Biomedical Review



Korea Biomedical Review
 
LG Chem launches Korea's 1st combination drug for diabetes, dyslipidemia 
Korea Biomedical Review
The drug comes amid the rising need for a treatment that covers both diabetes and dyslipidemia. Nine out of 10 diabetic patients are diagnosed with dyslipidemia, according to the Guideline for the Treatment of Dyslipidemia published by the Korean ...

 


Dyslipidemia in Children With HIV Started on Antiretroviral Therapy - Infectious Disease Advisor



Infectious Disease Advisor
 
Dyslipidemia in Children With HIV Started on Antiretroviral Therapy 
Infectious Disease Advisor
Lipid panel, plasma viral load, and CD4 cell counts were obtained at baseline, 6 months, and 12 months. This article is part of Infectious Disease Advisor's coverage of IDWeek 2017?, taking place in San Diego, CA. Our on-site staff will be reporting ...

 


'Alarming' Increase in Stroke Risk Factors - Medscape



Medscape
 
'Alarming' Increase in Stroke Risk Factors 
Medscape
Despite many prevention initiatives, the prevalence of conventional stroke risk factors, including hypertension, diabetes, dyslipidemia, drug abuse, and smoking, actually appears to be on the rise among new ischemic stroke patients in the United States ...

 


Association of vitamin D receptor gene polymorphisms with diabetic dyslipidemia in the elderly male population in ... - Dove Medical Press



Association of vitamin D receptor gene polymorphisms with diabetic dyslipidemia in the elderly male population in ... 
Dove Medical Press
Background: The prevalence of dyslipidemia is rising alarmingly in elderly Han Chinese male patients with type 2 diabetes mellitus (T2DM). The genetic factors that contribute to the development of diabetic dyslipidemia remain incompletely identified.

 


Dyslipidemia Drugs Market Key Trends and Opportunity Analysis 2023 - Edition Truth



Dyslipidemia Drugs Market Key Trends and Opportunity Analysis 2023 
Edition Truth
The top five players in the Global Dyslipidemia Drugs Market are AstraZeneca plc., Merck & Co., Inc., Pfizer, Inc., Daiichi Sankyo Company, Limited, and Abbott Laboratories. The cumulative share of these players in the global market was valued at 74.4 ...
Global Dyslipidemia Drugs Market 2017: AstraZeneca, Merck, Pfizer, Bayer, Abbott Laboratories, Mylan, Novartis, Amgen Digital Journal

all 2 news articles » 


Should We All Be Taking Statins? - Forbes



Forbes
 
Should We All Be Taking Statins? 
Forbes
Most people already know their status for the first 3, but "dyslipidemia" needs a bit more explanation. This is simply an unhealthy level of blood cholesterol, defined by USPSTF as either "an LDL-C level greater than 130 mg/dL or a high-density ...

 


Global Dyslipidemia Drugs Market Status and Forecast 2022 - Merck, Pfizer, Sanofi - Digital Journal



Global Dyslipidemia Drugs Market Status and Forecast 2022 - Merck, Pfizer, Sanofi 
Digital Journal
Brooklyn, NY -- (SBWIRE) -- 10/06/2017 -- Qyresearchreports include new market research report "Global Dyslipidemia Drugs Market Size, Status and Forecast 2022" to its huge collection of research reports. The exhaustive report here summarizes different ...

and more » 


Global Dyslipidemia Drugs Market to Grow at a High CAGR of around 5.27% by 2021- Key Vendors, Trends ... - MilTech



Global Dyslipidemia Drugs Market to Grow at a High CAGR of around 5.27% by 2021- Key Vendors, Trends ... 
MilTech
Dyslipidemia Drugs Market report delivers a detailed study with present and upcoming Opportunities to clarify the future investment in the market. Global Dyslipidemia Drugs industry 2017-2021 report shares information regarding key drivers, challenges ...

and more »